Bradoral 0.5 mg Lozenges
1. Disclaimer
This information is provided for educational and general drug-information purposes only. It is not a substitute for the official package leaflet, professional prescribing information, or advice from a qualified physician or pharmacist. Dosage, indications, precautions, and availability may vary by country, formulation, age group, and the currently authorized product information. Medical decisions should be based on the current official information applicable to the specific product.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
2. Summary
Bradoral is a domiphen bromide 0.5 mg oral lozenge intended for local antiseptic use in the mouth and throat. Domiphen bromide is a long-chain quaternary ammonium antiseptic and is classified under ATC A01AB06 (domiphen) for local oral anti-infective and antiseptic treatment.
Historical product information describes its use for prevention of mouth and throat inflammation when the risk of infection is increased and for symptomatic relief in conditions involving sore throat, difficulty swallowing, hoarseness, gingivitis, and aphthous stomatitis. Evidence specifically supporting domiphen in oral infectious diseases exists, but much of the published clinical evidence is old and relatively limited.
3. Brand Name
Bradoral® 0.5 mg Lozenges
The name Bradoral is also indexed as a trade name associated with domiphen bromide.
4. Category
Therapeutic category: Local oral antiseptic / anti-infective
Clinical category: Mouth and throat antiseptic; sore-throat preparation
ATC: A01AB06 – Domiphen, under local oral anti-infectives and antiseptics.
5. Active Ingredient
Domiphen bromide
Chemical names include dodecyldimethyl(2-phenoxyethyl)ammonium bromide and related systematic names. Domiphen is the pharmacologically relevant cation; domiphen bromide is the bromide salt used in pharmaceutical preparations.
6. Pharmaceutical Form & Strength
Pharmaceutical form: Oral lozenge for slow dissolution in the mouth
Strength: 0.5 mg domiphen bromide per lozenge
Pack size: 20 lozenges in the commonly listed Egyptian presentation.
Historical product information also describes eucalyptol and menthol/essential-oil flavoring components among the excipients, although the complete qualitative and quantitative excipient composition should be confirmed from the current package leaflet of the specific product.
7. Manufacturer & Marketing Authorization Holder
Current Egyptian market information: Several Egyptian medicine databases currently list GlaxoSmithKline (GSK) in connection with Bradoral and some retain the historical lineage Novartis > GlaxoSmithKline.
Historically documented product information: Novartis Pharma S.A.E., Cairo, under licence from Novartis Consumer Health SA, Nyon, Switzerland.
Important status qualification: I could not verify from a current publicly accessible EDA authorization record that the present-day Egyptian marketing authorization holder for Bradoral itself remains GSK. In the EDA January 2026 OTC list that was located, Bradoral is not listed; a different domiphen-bromide product, Bradozen 0.5 mg lozenges, is listed. Accordingly, the current MAH should be confirmed from the product’s current Egyptian registration/official packaging rather than inferred from historical corporate ownership.
8. Mechanism of Action
Domiphen bromide is a cationic quaternary ammonium antiseptic with properties similar to other cationic surfactants. Its antiseptic action is believed to occur mainly through interaction with and disruption of the cell membrane of susceptible microorganisms, ultimately impairing cellular integrity and viability.
9. Spectrum of Activity
Historical Bradoral information describes activity against many bacteria and fungi capable of causing infections of the mouth and throat, with Gram-positive organisms generally more susceptible than Gram-negative organisms.
Domiphen has demonstrated antimicrobial activity against various oral microorganisms in experimental and clinical research. However, the evidence should not be interpreted as establishing effectiveness against every cause of sore throat or oral infection. Published clinical evidence specifically evaluating domiphen is relatively limited and predominantly older.
10. Pharmacokinetics
Specific pharmacokinetic information for domiphen bromide is limited. Historical product information states that systemic concentrations are very low and that systemic absorption is considered insignificant or minimal at the intended local-use exposure.
Reliable contemporary data defining oral absorption, distribution, metabolism, and elimination quantitatively for the Bradoral lozenge were not identified. Therefore, detailed pharmacokinetic parameters such as bioavailability, half-life, volume of distribution, and clearance should not be assumed for this product.
11. Indications
According to the historical Bradoral product information, the lozenges were used:
- To help prevent inflammation of the mouth and throat when the risk of infection was increased.
- For local symptomatic relief in conditions associated with sore throat, difficulty swallowing, hoarseness, gingivitis, and aphthous stomatitis when infection was already present.
Clinical studies of domiphen bromide have reported improvement in pain and inflammation in some patients with acute infectious oral/dental diseases, although the available studies are small and old and do not establish that domiphen is an appropriate substitute for treatment of serious or specific bacterial infections.
12. Administration
Bradoral is administered by slowly dissolving the lozenge in the mouth rather than swallowing it whole.
The historical product dosage was:
For prophylactic use: 1 lozenge 4–6 times daily.
When infection had already occurred: 1 lozenge every 1–2 hours, with a stated maximum of 8 lozenges per day.
Because current Egyptian labeling could not be independently verified from a current Bradoral official leaflet, the current package leaflet should take precedence over historical dosing information.
Do not exceed the stated maximum dose.
13. Method of Preparation
Not applicable. Bradoral lozenges are a ready-to-use dosage form and require no mixing, dilution, reconstitution, or other preparation.
For administration, place the lozenge in the mouth and allow it to dissolve slowly. It should not be treated as an ordinary tablet intended to be swallowed immediately.
14. Contraindications
The primary documented contraindication is:
Known hypersensitivity to domiphen bromide or any component of the product.
The complete contraindication information should be checked against the current official leaflet for the particular marketed formulation.
15. Warnings & Precautions
Treatment should be discontinued and medical advice sought if difficulty in swallowing develops or becomes worse during treatment, because this may represent a significant local reaction or a condition requiring medical assessment.
When used for self-medication, medical assessment is appropriate if symptoms persist for approximately 5 days or fever develops, according to the historical Bradoral information.
Bradoral should not be assumed to be sufficient treatment for severe, persistent, or clinically significant infection. The underlying cause of a sore throat or oral lesion may require a different treatment.
Although the product has historically been described as suitable for children because of its taste, the available historical information does not establish a universally applicable pediatric age limit or pediatric dosing schedule. Age-specific use should therefore follow the current product leaflet or professional advice rather than being inferred from palatability.
16. Drug Interactions
Important local chemical incompatibilities have been documented.
Anionic surfactants, including soaps, can reduce the antiseptic activity of domiphen. Protein-containing organic material, such as blood and purulent secretions, may also diminish antiseptic activity.
Because systemic absorption is considered minimal, clinically significant systemic drug–drug interactions would not be expected to be a major feature of the product; nevertheless, this does not replace review of the current official product information for a particular patient.
17. Side Effects
Historically reported adverse effects are uncommon.
The documented reactions include local hypersensitivity reactions, particularly:
- Redness of the oral mucosa.
- Swelling of the pharyngeal mucosa.
- Associated difficulty in swallowing.
The historical information describes these reactions as very rare. Contemporary incidence data specific to Bradoral were not identified in the sources reviewed.
Any clinically significant swelling of the throat, breathing difficulty, rapidly worsening swallowing difficulty, or other signs suggestive of a serious allergic reaction require urgent medical evaluation.
18. Use in Special Populations
Pregnancy: Historical Bradoral information reported no evidence of developmental harm from many years of therapeutic experience but stated that, during the first three months of pregnancy, the product should be used only for compelling reasons.
Because this recommendation comes from historical product information and contemporary pregnancy-specific evidence for the Bradoral lozenge is limited, pregnant patients should use the product only after confirming its appropriateness with a physician or pharmacist.
Breastfeeding: Specific modern clinical data on domiphen bromide exposure through breast milk were not identified. Historical product information did not provide evidence of clinically important systemic exposure, but this should not be treated as proof of safety during lactation. Professional advice is appropriate when treatment is required during breastfeeding.
Children: No reliable current universal pediatric age/dose recommendation for Bradoral was independently verified. Do not infer pediatric dosing solely from the fact that the historical product description mentions acceptable taste.
Older adults: No specific age-related pharmacokinetic adjustment was identified. Use should follow the current product information and the patient's clinical circumstances.
19. Storage Conditions
The historical Bradoral instructions specify:
Store below 30°C and protect from moisture and heat.
Keep the medicine out of the reach of children.
The storage conditions printed on the current package should take precedence if they differ.
20. Additional Sections
Current Egyptian-Market Status
Egyptian medicine-information sources currently continue to list Bradoral 0.5 mg, 20 lozenges, with a price of approximately EGP 5.75 in listings updated in September 2026.
However, the Egyptian Drug Authority January 2026 OTC list located during verification does not contain Bradoral, while it does list Bradozen 0.5 mg lozenges containing domiphen bromide. This discrepancy means that online market listings should not by themselves be treated as confirmation of current regulatory authorization or uninterrupted availability of Bradoral.
Clinical Evidence
Controlled clinical studies published in 1983 reported beneficial effects of domiphen bromide in acute infectious oral/dental diseases, including reductions in pain and inflammation. These studies were small, and their age limits the strength of conclusions that can be drawn about modern clinical practice.
Important Clinical Limitation
Bradoral is a local antiseptic lozenge, not a systemic antibiotic. Its antimicrobial action should not be interpreted as treatment for every bacterial, viral, fungal, or other cause of sore throat or oral disease.
21. Frequently Asked Questions (FAQ)
What is Bradoral 0.5 mg?
It is a mouth-and-throat lozenge containing 0.5 mg of domiphen bromide, a quaternary ammonium local antiseptic.
How should Bradoral be taken?
The lozenge is allowed to dissolve slowly in the mouth. Historical dosing information describes 4–6 lozenges per day for prophylactic use and one every 1–2 hours for established symptoms, with a maximum of 8 lozenges daily. Current official labeling should take precedence.
Is Bradoral an antibiotic?
No. Domiphen bromide is a topical quaternary ammonium antiseptic. It is not a conventional systemic antibiotic.
Can Bradoral be used during pregnancy?
Historical information advised particular caution during the first three months of pregnancy. Because current pregnancy-specific evidence is limited, use during pregnancy should be discussed with a healthcare professional.
When should medical advice be sought for a sore throat while using Bradoral?
Medical assessment is appropriate when symptoms persist for about 5 days, when fever develops, or sooner when swallowing becomes difficult or progressively worse.
22. References
Historical Bradoral product information — composition, dosage, indications, precautions, pregnancy information, adverse effects, interactions, storage, and manufacturer information.
PubChem – Domiphen / Domiphen Bromide — chemical identity, pharmacological classification, trade names, and ATC information.
WHO ATC classification data — A01AB06, domiphen, local oral anti-infectives and antiseptics.
Scaglione F, Scarpazza G, Marchi E, Biella G, Fraschini F. Evaluation of domifen bromide in the treatment of acute infectious oral diseases. International Journal of Clinical Pharmacology Research. 1983;3(4):261–264.
Scaglione F, Coduri M, Nebuloni R, Fraschini F. Activity and tolerability of domifen bromide in patients affected by acute infectious dental diseases: a double-blind placebo-controlled trial. International Journal of Clinical Pharmacology Research. 1983;3(5):357–361.
Egyptian Drug Authority – OTC List, January 2026 — current publicly accessible OTC listing reviewed for domiphen-containing products; Bradoral was not found in the document, while Bradozen 0.5 mg lozenges containing domiphen bromide were listed.
Egyptian drug-information listings, 2026 — current online listings for Bradoral 0.5 mg/20 lozenges and associated manufacturer/market information.